You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1608 Results
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Updated
Mar 2025
Document
New
Apr 2025
Document
New
Apr 2025
Guidelines and Advice
Status: In-Review
ID: GL MOTAC-4
Version: 2
Jan 2022
Guidelines and Advice
Status: In-Review
ID: GL-END 3-21
Jan 2018
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Document
New
Apr 2025
Guidelines and Advice
Status: In-Review
ID: 17-9
Dec 2014
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut),
CARBOplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025

Pages